No Data
No Data
H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
Express News | Annovis Bio Inc - Combination Therapies Show Improved Cognition in Alzheimer's Models
Express News | Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $26
Buy Rating on Annovis Bio Amid Progress in PD and AD Drug Development